Silverback Therapeutics Inc. (SBTX): Price and Financial Metrics


Silverback Therapeutics Inc. (SBTX): $5.87

0.06 (+1.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SBTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SBTX Stock Price Chart Interactive Chart >

Price chart for SBTX

SBTX Price/Volume Stats

Current price $5.87 52-week high $8.97
Prev. close $5.81 52-week low $2.80
Day low $5.72 Volume 116,700
Day high $6.15 Avg. volume 337,931
50-day MA $5.39 Dividend yield N/A
200-day MA $4.38 Market Cap 211.66M

Silverback Therapeutics Inc. (SBTX) Company Bio


Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.


SBTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SBTX Latest Social Stream


Loading social stream, please wait...

View Full SBTX Social Stream

Latest SBTX News From Around the Web

Below are the latest news stories about SILVERBACK THERAPEUTICS INC that investors may wish to consider to help them evaluate SBTX as an investment opportunity.

Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment

ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax

Yahoo | July 22, 2022

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T

Yahoo | July 21, 2022

What You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor Composition

The big shareholder groups in Silverback Therapeutics, Inc. ( NASDAQ:SBTX ) have power over the company. Large...

Yahoo | June 22, 2022

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

Yahoo | May 17, 2022

JonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)

JonesTrading analyst Soumit Roy maintained a Hold rating on Silverback Therapeutics (SBTX – Research Report) on May 13. The company's shares closed last Friday at $2.96, close to its 52-week low of $2.80. According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.2% and a 28.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Silverback Therapeutics with a $3.43 average price target, an 11.0% upside from current levels. In a report issued on May 13, H.C.

Christine Brown on TipRanks | May 15, 2022

Read More 'SBTX' Stories Here

SBTX Price Returns

1-mo -2.33%
3-mo N/A
6-mo 47.86%
1-year -13.42%
3-year N/A
5-year N/A
YTD -11.86%
2021 -85.63%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6497 seconds.